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Abstract
Background: Little is known of the prevalence of hepatitis B virus (HBV) infection and its effect on choice of therapy
and disease course in patients with inflammatory bowel disease (IBD). We assessed the prevalence of HBV in Hong
Kong as well as determinants of altered transaminases, effects of HBV infection on therapeutic strategy and clinical
course in IBD.
Methods: In this retrospective cohort, hepatitis B surface antigen (HBsAg), liver function tests, and IBD disease
characteristics were recorded. Logistic regression was used to identify factors associated with altered transaminases.
Results: Four hundred six IBD patients were recruited. HBV infection was found in 5.7 % patients in Hong Kong.
The use of steroids (OR, 2.52; p = 0.010) and a previous history of surgery (OR 2.33; p = 0.026) were associated with
altered transaminases in IBD. There was no significant difference in disease control and use of IBD medication
between HBsAg-positive and HBsAg-negative IBD patients.
Conclusion: The prevalence of HBV among patients with IBD in Hong Kong (5.7 %) is similar to that of general
population (~7 %). There was no difference in disease control and use of IBD medication between subjects with
or without HBV.
Keywords: Inflammatory bowel disease, Hepatitis B, Immunosuppression
Abbreviation: 5ASA, 5-aminosaliylic acid; AGA, American Gastroenterological Association Institute; ALT, Alanine
aminotransferase; CD, Crohn’s disease; CI, Confidence interval; CRP, C reactive protein; ESR, Erythrocyte
sedimentation ratio; HBeAg, Hepatitis e antigen; HBsAg, Hepatitis B surface antigen; HBV, Hepatitis B virus;
HCC, Hepatocellular carcinoma; IBD, Inflammatory bowel disease; OR, Odds ratio; SD, Standard deviation;
TPN, Total parental nutrition; UC, Ulcerative colitis; ULN, Upper limit of normal
Background
Previously a disease predominantly of the West, there is
now a rising incidence and prevalence of inflammatory
bowel disease (IBD) in Asia [1, 2]. Immunosuppressive
therapy is the mainstay of therapy of IBD. However, it
can be associated with complications such as the reacti-
vation of hepatitis B virus (HBV) [3–5]. This is of
particular importance in Asian countries which have a
moderate to high prevalence of HBV infection [6]. Several
studies from the West have reported the prevalence of
HBV infection in IBD patients [7–10]. However current
data on whether IBD patients have a higher risk of HBV
infection have been conflicting. There is also a paucity of
data on the prevalence of HBV infection among IBD
patients in Southeast Asia.
International guidelines recommend that all hepatitis
B surface antigen (HBsAg)-positive IBD patients should
receive anti-viral prophylaxis before starting immuno-
suppressive agents [11–14]. However, the risk of reactiva-
tion appeared to be related to the type and magnitude of
immunosuppression [15]. The American Gastroentero-
logical Association Institute (AGA) recently recommends
that only patients at moderate to high risk undergoing
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immunosuppressive therapy should have anti-viral
prophylaxis [16]. However, there is still a paucity of
data in supporting this new recommendation.
In addition, it is currently unclear if the presence of
HBV infection in IBD patients influence the disease
behavior or clinical course of IBD itself. It has been
reported that IBD patients with chronic HBV have a
worse prognosis than their non-infected counterparts
due to the infrequent use of immunosuppressant [17].
In this study we assessed the prevalence of HBV infec-
tion in patients with IBD in ethnically Chinese individuals
from Hong Kong. We also evaluated the determinants of
altered transaminases and the effect of HBV infection




In this retrospective cohort study, all IBD patients aged
18 years or older with a diagnosis of Crohn’s disease
(CD) or ulcerative colitis (UC) for at least 3 months de-
fined by histology, endoscopy or radiology attending the
IBD clinic at the Prince of Wales Hospital from the
period of June 2012 to June 2013 were included. All
patients had their hepatitis B status checked during the
study period.
They were further assessed to investigate the determi-
nants of altered transaminases in IBD patients, the charac-
teristics of hepatitis B patients with altered transaminases
and to compare IBD patients with and without hepatitis B.
Patients were followed up at 3- to 6-monthly intervals.
The clinical phenotypes of IBD were classified according
to the Montreal Classification [18] and disease activity
was recorded prospectively at each visit. Assessment was
based on the physician’s global assessment, taking into
account the patient’s symptoms, inflammatory markers
and recent endoscopic assessment. Disease control was
recorded as well-controlled or not well-controlled. Elec-
tronic hospital record was reviewed for a history of IBD
related surgery and hospital admissions. A history of
IBD-associated liver disease (e.g., primary sclerosing
cholangitis) was recorded. Active smoker was defined as
subjects who smoke at least 1 cigarette daily in the past
6 months. Ex-smoker was defined as patients who
smoked at least 1 cigarette daily but had quitted for at
least 6 months. Non-smoker was defined as patients
who had never smoked. All patients were tested negative
for hepatitis A and hepatitis C.
Blood tests including complete blood count, renal and
liver function tests, inflammatory markers [Erythrocyte
Sedimentation Ratio (ESR) or C reactive protein (CRP)]
were monitored during each clinic visit. The use of IBD
medications including 5-aminosaliylic acid (5ASA), corti-
costeroids, thiopurine (azathioprine/6-mercaptopurine),
methotrexate and anti-tumor necrosis factor antibody
(Infliximab or Adalimumab) were reviewed from the time
of diagnosis until last follow-up. The duration and dosage
of these medications were recorded.
Chronic hepatitis B was defined as positive HBsAg for
more than 6 months. Patients who had a positive HBsAg
were tested for hepatitis e antigen (HBeAg) and serum
HBV-DNA. We did not include patients with occult
hepatitis B (anti-HBc positive; HBsAg negative) patients
as the risk of hepatitis flare in occult HBV patients was
rare in patients receiving common medications for IBD.
If the patient had been put on antiviral agents, their
baseline HBV-DNA level was recorded. A history of liver
cirrhosis and hepatocellular carcinoma (HCC) were re-
corded. A diagnosis of liver cirrhosis was made by clinical,
laboratory and imaging criteria while that of HCC was
confirmed by tumor markers, imaging +/− biopsy results.
All IBD patients with HBV were invited to have their
liver stiffness measured by transient elastography. The
use of anti-viral agents for the treatment of chronic
hepatitis B, including the dosage and duration were
recorded.
Abnormal liver function (altered transaminases) was de-
fined as serum Alanine Aminotransferase (ALT) level twice
the upper limit of normal (ULN) (i.e., ALT >110 IU/mL).
In order to distinguish between altered transaminases
due to IBD and reactivation of hepatitis B, in IBD patients
with hepatitis B who had altered transaminases, details of
the episode of liver enzymes elevation were reviewed.
Medications used at the time of altered transaminases and
the HBV DNA levels were recorded. Altered transami-
nases related to HBV reactivation was considered prob-
able when an increase in ALT was observed in the
absence of other potential causative factors (including
other viral hepatitis) and HBV DNA values were elevated.
Transient elastography
Fibroscan (Echosens, Paris, France) was performed by
the principal investigator (HC) who had received formal
accredited training. Fibroscan were performed at the
time of study. The median of 10 successful acquisitions
was kept as representative of liver stiffness. Liver stiff-
ness measurements were considered reliable only if 10
successful acquisitions were obtained and the interquartile
range to median ratio of the 10 acquisitions was < 30 %.
Advanced liver fibrosis and cirrhosis were defined ac-
cording to the transient elastography algorithm for
chronic hepatitis B previously validated against liver hist-
ology. Patients with normal ALT and liver stiffness >9.0 kPa
or raised ALT (1-5x ULN) and liver stiffness >12.0kPa were
considered to have liver fibrosis and those with normal
ALT and liver stiffness >12.0 kPa or raised ALT (1-5x ULN)
and liver stiffness >13.4 kPa were considered to have liver
cirrhosis [19].
Chan et al. BMC Gastroenterology  (2016) 16:100 Page 2 of 8
Matching with chronic hepatitis B patients without IBD
Cases (HBsAg-positive IBD) were defined as IBD patients
tested positive for HBsAg. Controls consisted of HBV pa-
tients without IBD, selected from a cohort of previous
hepatitis B studies. Controls were matched 3:1 to cases by
age (+/− 3 years), gender, HBeAg status and use antiviral
agents [20]. As the major risk factors for HBV infection in
Asia are through vertical transmission, patients usually
acquire the infection early in childhood. With matching
of age, the duration of HBV infection is likely similar
between cases and controls. Liver stiffness and HBV
DNA level (baseline HBV DNA level if patient had been
put on anti-viral agents) were recorded. Differences in
liver stiffness and HBV DNA level between cases and
controls were assessed.
Statistical analysis
Results were expressed as mean with standard deviation
(SD) or number- with percentages. Unpaired t-test was
used to test the differences in continuous variables and
Chi-squared test for categorical variables. Univariate
analysis was used to identify factors associated with
altered transaminases. Factors with a P value of less than
0.1 were included in the multivariate analysis, performed
by binary logistic regression. Risks were expressed as
odds ratio (OR) with 95 % confidence interval (CI). A p
value <0.05 was considered significant. All statistical
analyses were performed using SPSS 14.0 for Windows
software package.
Results
Demographics and characteristics of IBD
Four hundred six IBD patients were recruited (185 CD
and 221 UC). The characteristics of the IBD patients in
Hong Kong are tabulated in Table 1. The median time
of follow up from diagnosis was 8 years (range 1–29)
One patient had IBD-associated liver disease (namely,
primary sclerosing cholangitis) in our cohort. This patient
had cholestatic liver dysfunction with alkaline phosphatase
fluctuating between 150 and 300 IU/L. She did not ex-
perience any episodes of altered transaminases.
Prevalence of HBsAg positivity
In Hong Kong, 5.7 % IBD patients had positive HBsAg
(6.5 % CD; 5.0 % in UC).
Determinants of altered transaminases
Altered transaminases were observed in 58 IBD patients
(14.4 %). Among the patients with history of altered trans-
aminases, the median ALT was 199 IU/L (range 112 to
2520). None of the patients had liver failure or required
liver transplantation. Results of univariate analysis are
shown in Table 2a. In multivariate analysis, the use of ster-
oid [OR 2.524, 95 % confidence interval (CI) 1.398–6.450]
and a previous history of IBD related surgery (OR 2.330,
95 % CI 1.107–4.906) were independently associated with
of altered transaminases (Table 2b).
Clinical outcomes of HBsAg-positive and HBsAg-negative
IBD Patients
There was no significant difference between HBV and
non-HBV IBD patients in terms of disease location and
behavior (Table 3). There was a significantly higher
rate of use of biologics in patients with positive HBsAg
(p = 0.030), but there was no significant difference in
the use of other IBD medications. One HBsAg-negative
patient died during the study period because of chest
infection.
IBD patients with HBV
Among the 23 IBD patients with HBV, 12 (52.2 %) of
them were men, with a mean age of 44.1 years (SD, 9.5).
The mean age at the time of IBD diagnosis was 31 years
(SD, 13.9). The median time of follow up among IBD pa-
tients with HBV was 13 years (range 3–24 years). Of the
23 HBsAg-positive IBD patients, 3 (13.0 %) were HBeAg
positive. Six of the patients were receiving antiviral agents,
one was receiving lamivudine and five were receiving






Age (mean ± SD) 40.6 ± 14.3 48.4 ± 14.0
Age at diagnosis (mean ± SD) 32.1 ± 14.1 38.6 ± 13.1





































IBD, inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis
aNot mutually exclusive
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entecavir. None of our patients received interferon treat-
ment. 18 (78.3 %) patients had detectable HBV DNA and
10 (23.4 %) of them had HBV DNA >2000 IU/mL. The
mean serum HBV DNA level was 3.41log IU/mL (SD,
2.10) in HBsAg positive IBD patients which is similar to
HBsAg positive controls without IBD (4.12 log IU/mL;
SD, 1.69; p = 0.319). 1 (4.3 %) HBsAg positive IBD pa-
tients had cirrhosis and 6 (8.7 %) HBsAg positive con-
trols without IBD had cirrhosis (p = 0.494). The rate of
HCC were also comparable between HBsAg positive
IBD patients (0; 0 %) and HBsAg positive controls with-
out IBD (1; 1.5 %) (p = 0.494).
The 13 patients who had immunosuppressive therapy,
5 (38.4 %) were also receiving antiviral prophylaxis.
There was no difference in the mean HBV DNA level
in patients who were receiving immunosuppressants
compared with those who were not [3.89 log IU/mL
(SD, 2.23) versus 3.57log IU/mL (SD, 2.14); p = 0.731].
Cause of altered transaminases in HBsAg-positive
IBD patients
The characteristics of IBD patients with HBV who expe-
rienced altered transaminases were summarized in
Table 4. None of these patients had evidence of IBD-
associated liver disease.
Among the six HBsAg-positive patients with altered
transaminases, two patients had possible hepatitis B reacti-
vation. Both of them were receiving steroid without anti-
viral prophylaxis at the time of altered transaminases. The
first patient was put on budesonide 9 mg daily for 4 weeks
and azathioprine (2 mg/kg) for mildly active ileocolonic
Crohn’s disease. He was noted to have persistently elevated
ALT up to 146 with elevated serum HBV DNA 7.85 log
IU/mL. Steroid was stopped, azathioprine was changed to
6-mercaptopurine and mesalazine was added. Entecavir
was started in view of possible hepatitis B reactivation and
his serum HBV DNA level was subsequently undetectable
and liver function remained normal. His underlying
Crohn’s disease is well controlled with mesalazine and
6-mercaptopurine (0.5 mg/kg). Another patient had
systemic steroid in private sector (exact duration and
dosage unknown) and developed altered transaminases
with highest ALT up to 2520 with HBV DNA 7.07 log
IU/mL but no fulminant liver failure was observed. He
was treated as hepatitis reactivation and lamivudine
was started. His liver function was subsequently normal-
ized and maintained normal. His underlying ulcerative
colitis was well controlled with 5-ASA.










Age, years (Mean ± SD) 44.6 ± 15.1 46.6 ± 12.1 – 0.333
Age at diagnosis,
years (Mean ± SD)
35.5 ± 14.0 36.8 ± 13.7 – 0.481
Sex, male (n; %) 206 (59.2 %) 35 (60.3) 0.953 0.869
Crohn’s vs ulcerative
colitis (ratio)
0.775 1.43 0.588 0.063
Previous surgery
(n; %)
42 (12.1) 16 (27.6) 2.776 0.002
Use of 5-ASA (n; %) 177 (50.9) 17 (29.3) 0.401 0.003
Use of thiopurines
(n; %)
130 (37.3) 31 (53.4) 1.908 0.024
Use of steroids (n; %) 42 (12.1) 18 (31.0) 3.279 <0.001
Use of anti-TNF agents
(n; %)
7 (2.0) 2 (3.4) 1.74 0.497
HBsAg positivity
(n; %)
17 (4.9) 6 (10.3) 2.24 0.104
HBV and thiopurines
(n; %)
10 (3) 3 (5.2) 1.833 0.369
HBV and steroids
(n; %)
3 (0.6) 3 (1.7) 3.035 0.368
HBV and anti-TNF
agents (n; %)
1 (0.3) 1 (1.7) 6.088 0.204
b) Multivariate analysis




Previous Surgery 2.330 (1.107–4.906) 0.026
5-ASA 0.428 (0.197–1.163) 0.058
Steroids 2.524 (1.394–6.450) 0.010
Thiopurines 0.698 (0.307–1.695) 0.411
5ASA 5-aminosalicylic acid
Table 3 Comparison of clinical demographics between IBD






Age (Mean ± SD)a 44.1 ± 9.5 44.9 ± 13.9 0.783




Previous surgery (n; %)b 5 (21.7) 53 (13.8) 0.298
Disease Flare (n; %)b 8 (8.7) 59 (10.6) 0.770
Admission (n; %)b 7 (30.4) 69 (18) 0.145
5ASA (n; %)b 8 (34.8) 186 (48.5) 0.199
Thiopurine (n; %)b 13 (56.5) 148 (38.6) 0.093
Steroid (n; %)b 6 (26.1) 54 (14.1) 0.116
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Table 4 Characteristics of HBsAg positive IBD patients with altered transaminases




HBV DNA level at time
of altered transaminase
IBD medications Possible cause of altered
transaminase
Use of antiviral prophylaxis
at time of altered transaminase
33 M CD -ve 176 17 40 4.21 log IU/mL 5ASA Likely immune clearance phase
with hepatitis B e-seroconversion
No
38 M CD +ve 146 14 38 7.85log IU/mL Thiopurines, steroid Possible hepatitis B reactivation
vs azathioprine related liver
dysfunction
No
53 M UC +ve 2520 55 32 7.07log IU/mL 5ASA, Steroid Possible hepatitis B reactivation No
46 M CD -ve 162 12 38 4.02log IU/mL Thiopurines Transient liver dysfunction with
uncertain cause
No
32 F UC -ve 207 9 41 2.44log IU/mL 5ASA Likely related to hyperemesis
gravidum
No
36 F CD +ve 592 11 26 Undetectable Thiopurines, Steroid, Biologics, Possibly related to TPN; unlikely
related to hepatitis B reactivation
Yes













Liver stiffness and HBV DNA levels results
We compared liver stiffness using Fibroscan and DNA
levels of HBsAg-positive IBD patients were compared
with HBsAg-positive controls without IBD. Fibroscan
was performed in 21 of the 23 patients with both HBV
and IBD. One patient was lost to follow up after initial
inclusion and another patient refused Fibroscan. One
patient (4.3 %) had confirmed liver cirrhosis by Fibros-
can measurement. None had significant fibrosis. The
mean liver stiffness in the cases was 5.8kPa (SD 2.3)
while that in the matched controls was 7.0kPa (SD 3.3)
(p = 0.081). The mean HBV DNA level was 3.76log IU/mL
(SD 2.12) and 4.12log IU/mL (SD 2.15) (p = 0.319).in
HBsAg-positive patients with IBD and without IBD,
respectively.
Discussion
Earlier studies have shown that patients with IBD have a
higher prevalence of HBV than that of the general popu-
lation [7]. In a recent paper fromChina, it was reported
that the prevalence of past HBV infection in IBD pa-
tients was higher than that of non-IBD patients [21].
These may be attributed by the increased needof surgery
and transfusion among IBD patients [21]. However, in a
separatepaper it was shown that the prevalence rate of
HBV infection in IBD patients was similar to that of the
general population of China [22].
In Hong Kong, the prevalence of hepatitis B among
IBD subjects was 5.7 % and this figure is comparable to
the background population (around 7 %) [6].
Huang et al. reported that the prevalence of occult
HBV infection in IBD patients was higher than that of
non-IBD patients in Shanghai, China [21]. However, we
included HBsAg-positive IBD patients but excluded
IBD patients with antibodies to hepatitis B core antigen
(anti-HBc) alone or occult HBV infection. Routine
checking of anti-HBc to identify patients with occult
HBV has been recommended for patients receiving
chemotherapy [23]. However, acute hepatitis flare in
occult HBV patients is very rare in patients receiving
common medications for IBD unless patients were also
receiving biologic agents [15]. Therefore, we sought to
include only patients at a high risk of HBV reactivation.
Altered transaminases was not uncommon and was
observed in 14.4 % of our IBD patients. Among those
who were positive for HBV, 26 % had altered transami-
nases. The prevalence of altered transaminases among
IBD patients with HBV was reported to be 36 % [15],
17 % [17] and 16 % [24], in studies from Spain, Korea
and Hong Kong, respectively. The rate of altered trans-
aminases among IBD patients with HBV is lower in Asia.
The severity of altered transaminses appeared to be
more severe in the Spanish population as 24 % of those
with altered transaminases developed liver failure and
half required liver transplantation [15], while <1 % was
observed in a Korean cohort [17] but none in our cohort
or in separate Chinese cohort [24].
Ng et al. reported that Caucasians are much more
likely to receive steroid in the first year of diagnosis than
that of Asian patients [2]. In addition, though not statis-
tically significant, Caucasians with HBV also appeared to
have a higher baseline HBV DNA than Asian patients
[25]. The combination of these factors may explain the
higher rate and severity of altered transaminases among
Caucasian IBD patients.
Most international guidelines recommend that all
HBV patients receiving immunosuppressants, regardless
of the drug, dosage or duration, should receive anti-viral
prophylaxis [11–14]. However, compliance rate with
such strategy is low in our cohort. Among patients with
positive HBsAg who received immunosuppressants, 38 %
received anti-viral prophylaxis. In Hong Kong, there is
limited or no reimbursement for antiviral prophylaxis and
this likely explains the low compliance rate.
It is well established that steroids increase viral replica-
tion and is associated with HBV reactivation [26]. Based
on our current findings, the risk of HBV reactivation ap-
peared to be low in patients receiving immunosuppressive
therapy in the form of thiopurines unless there was con-
comitant use of steroids. This finding echoes the recent
update AGA guideline which recommends that only pa-
tients at moderate to high risk undergoing immunosup-
pressive therapy should have anti-viral prophylaxis [16].
According to the AGA guideline, chronic hepatitis B or
occult hepatitis B patients treated with traditional im-
munosuppressive agents (e.g., azathioprine); chronic
hepatitis B or occult hepatitis B treated with any dose
of oral corticosteroids daily for ≤1 week were considered
low risk for hepatitis B reactivation. In these patients, anti-
viral prophylaxis is not recommended by the AGA [15].
Based on our results and the latest AGA recommenda-
tion, we suggest that close monitoring of liver function
and prompt initiation of anti-viral in case of altered trans-
aminases may be a reasonable option for IBD patients
with HBV treated with thiopurines.
We found that a past history of surgery and the use
of steroids were associated with altered transaminases.
The use of corticosteroid had been established to be
risk factor for secondary steatohepatitis [27]. The use
of total parental nutrition (TPN) may induce hepatos-
teatosis and result in altered transaminases. Although
we did not have complete data on the use of TPN in
our cohort, it is likely that patients with IBD receiv-
ing surgery would have received nutritional support
during the pre and peri-operative period and this
could account for the association of altered transami-
nases with surgery.
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International guidelines recommend that all IBD pa-
tients should be screened for HBV [3, 28]. From our
cohort, HBV infection per se was not associated with
altered transaminases. Among the HBV patients with
altered transaminases who were on immunosuppressant,
only one patient on steroid and another patient on steroid
and thiopurine had possible HBV reactivation. In the
other cases with altered transaminases, there was no
strong evidence of HBV reactivation.
Although more patients with HBV infection appeared
to have used biologics this observation should be inter-
preted with caution in view of the small sample size.
The frequency of use of other IBD medications including
steroids, 5-ASA and immunosuppressant in Hong Kong
was similar between HBV and non-HBV patients. In
Korea, HBsAg-positive patients had a lower rate of use
of immunosuppressant and had a worse outcome than
HBsAg-negative IBD patients. The authors contributed
the worse clinical outcome to the under-utilization of
immunosuppressants in patients with both diseases be-
cause of the fear of HBV reactivation [18]. The lack of
influence of HBV infection on the use of immunosup-
pressants may explain the similar clinical outcome re-
lated to IBD patients with HBV as compared to those
without HBV. We therefore believe that physicians
should prescribe IBD related medications to patients
based on their disease control regardless of their HBV
status so as to maintain good IBD control.
We did not exclude patients with primary sclerosing
from our study. Our study investigated the cause of
altered transaminases, as PSC predominantly affect alka-
line phosphatase (ALP), instead of transaminases (ALT),
including PSC in the cohort is unlikely to affect the
results. For instance, the only patient with PSC in our
cohort had cholestatic liver dysfucntion with normal
ALT, hence it is unlikely to be a confounding factor of
the study.
This study has several limitations. First, some of the
patients have been started on anti-viral agents before the
commencement of the study. Therefore the true effect
of immunosuppressant in HBV patients may be masked.
Prospective monitoring of the HBV DNA level and fol-
low up of liver stiffness measurement in anti-viral naïve
patients will provide further information on the true ef-
fect of immunosuppressant on HBV. Second, in Hong
Kong, all hospital records have been computerized since
early 2000, however, records before early 2000 may be
incomplete and hence some cases of altered transami-
nases could have been missed because of unavailable
data. Third, our cohort consisted of a modest number
of patients with both IBD and HBV who were treated
with immunosuppressants. Lastly, the size of the HBV
cohort was modest and thus the analysis may be
underpowered. However, the preliminary findings may
shed light on the characteristics of this special group
of IBD population.
Conclusions
In conclusion, the prevalence of HBV among patients
with IBD in Hong Kong was comparable to that of the
general population. The use of steroids and a history of
surgery were associated with altered transaminases in
IBD patients. There was however no difference in the
disease control and the choice or use of medications for
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